Kirsten Korsholm

Dr. Kirsten Korsholm

Rigshospitalet, Copenhagen University Hospital, Denmark
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Kirsten KorsholmKirsten Korsholm
Kirsten Korsholm
UFUlla Feldt-Rasmussen
Ulla Feldt-Rasmussen
HGHenrik Granqvist
Henrik Granqvist
LHLiselotte Højgaard
Liselotte Højgaard
BBBirgit Bollinger
Birgit Bollinger
ILIan Law
Ian Law
Fabry disease is a rare metabolic glycosphingolipid storage disease caused by deficiency of the lysosomal enzyme α-galactosidase A—leading to cellular accumulation of globotriasylceramide in different organs, vessels, tissues, and nerves. The disease is associated with an increased risk of cerebrovascular disease at a young age in addition to heart and kidney failure. The objective of this study was to assess brain function and structure in the Danish cohort of patients with Fabry disease in a prospective way using 18-fluoro-deoxyglucose (F-18 FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI). Forty patients with Fabry disease (14 males, 26 females, age at inclusion: 10–66 years, median: 39 years) underwent a brain F-18-FDG-PET-scan at inclusion, and 31 patients were followed with FDG-PET biannually for up to seven years. All patients (except one) had a brain MRI-scan at inclusion, and 34 patients were followed with MRI biannually for up to nine years. The FDG-PET-images were inspected visually and analysed using a quantitative 3-dimensional stereotactic surface projection analysis (Neurostat). MRI images were also inspected visually and severity of white matter lesions (WMLs) was graded using a visual rating scale. In 28 patients brain-FDG-PET was normal; in 23 of these 28 patients brain MRI was normal—of the remaining five patients in this group, four patients had WMLs and one patient never had an MRI-scan. In 10 patients hypometabolic areas were observed on brain-FDG-PET; all of these patients had cerebral infarcts/hemorrhages visualized on MRI corresponding to the main hypometabolic areas. In two patients brain-FDG-PET was ambiguous, while MRI was normal in one and abnormal in the other. Our data indicated that, in patients with Fabry disease, MRI is the preferable clinical modality—if applicable—when monitoring cerebral status, as no additional major brain-pathology was detected with FDG-PET.

30 May 2008 in NeuroImage
Verified
Journal Article
Closed access
Kirsten KorsholmKirsten Korsholm
Kirsten Korsholm
KMKristoffer Hougaard Madsen
Kristoffer Hougaard Madsen
JFJette Lautrup Frederiksen
Jette Lautrup Frederiksen
JRJames B. Rowe
James B. Rowe
TLTorben Ellegaard Lund
Torben Ellegaard Lund

12 December 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Kirsten KorsholmKirsten Korsholm
Kirsten Korsholm
RARamune Aleksyniene
Ramune Aleksyniene
EAElisabeth Albrecht-Beste
Elisabeth Albrecht-Beste
EVEva Soelberg Vadstrup
Eva Soelberg Vadstrup
FAFlemming Littrup Andersen
Flemming Littrup Andersen
BFBarbara Malene Fischer
Barbara Malene Fischer

1 January 2013 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
Kirsten KorsholmKirsten Korsholm
Kirsten Korsholm
ILIan Law
Ian Law
For a subpopulation of drug-resistant epilepsies, a ketogenic diet constitutes the treatment of choice. A ketogenic diet is a high-fat, low-protein, and low-carbohydrate diet, which induces ketosis. Despite the use in treatment of epilepsy since 1924, the clinical efficacy was not demonstrated in a controlled, randomized trial until 2008, showing its capability of reducing seizure frequency with more than 50%. However, the exact mechanism of this form of treatment is still unknown. We report here a patient with drug-resistant epilepsy on a ketogenic diet, where a brain 18F-FDG PET examination demonstrated a severely decreased uptake in the cerebral cortex bilaterally.

2 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Kirsten KorsholmKirsten Korsholm
Kirsten Korsholm
NONanna Overbeck
Nanna Overbeck
ADAndré H. Dias
André H. Dias
ALAnnika Loft
Annika Loft
FAFlemming Littrup Andersen
Flemming Littrup Andersen
BFBarbara Malene Fischer
Barbara Malene Fischer
Background: Total body and long-axial field-of-view (LAFOV) PET/CT represent visionary innovations in imaging enabling either improved image quality, reduction in injected activity–dose or decreased acquisition time. An improved image quality may affect visual scoring systems, including the Deauville score (DS), which is used for clinical assessment of patients with lymphoma. The DS compares SUVmax in residual lymphomas with liver parenchyma, and here we investigate the impact of reduced image noise on the DS in patients with lymphomas scanned on a LAFOV PET/CT. Methods: Sixty-eight patients with lymphoma underwent a whole-body scan on a Biograph Vision Quadra PET/CT-scanner, and images were evaluated visually with regard to DS for three different timeframes of 90, 300, and 600 s. SUVmax and SUVmean were calculated from liver and mediastinal blood pool, in addition to SUVmax from residual lymphomas and measures of noise. Results: SUVmax in liver and in mediastinal blood pool decreased significantly with increasing acquisition time, whereas SUVmean remained stable. In residual tumor, SUVmax was stable during different acquisition times. As a result, the DS was subject to change in three patients. Conclusions: Attention should be drawn towards the eventual impact of improvements in image quality on visual scoring systems such as the DS.

19 March 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Kirsten KorsholmKirsten Korsholm
Kirsten Korsholm
MRMichala Reichkendler
Michala Reichkendler
LALouise Alslev
Louise Alslev
ÅRÅse Krogh Rasmussen
Åse Krogh Rasmussen
POPeter Oturai
Peter Oturai
Our objective was to evaluate the frequency of malignancy in incidental thyroidal uptake on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in a cohort of Danish patients, and furthermore to evaluate the impact of thyroid scinti-graphy in the diagnostic work-up. All whole-body PET/CT reports from 1 January 2010 to 31 December 2013 were retrospectively reviewed and further analyzed if visually increased thyroidal FDG uptake was reported. Patient electronic files were searched for further thyroid evaluation. Of 13,195 18F-FDG-PET/CT scans in 9114 patients, 312 PET/CT reports mentioned incidental thyroid FDG-uptake, and 279 patients were included in the study (3.1%). The thyroid was further investigated in 137 patients (49%), and 75 patients underwent thyroid scintigraphy. A total of 57 patients had a thyroid biopsy and 21 proceeded to surgery. Surgical specimens displayed malignancy in 10 cases, and one thyroid malignancy was found by autopsy. Hence, 11 patients were diagnosed with thyroid malignancies among 279 patients with incidental thyroid 18F-FDG uptake (3.9%). In 34 patients, a biopsy was avoided due to the results of the thyroid scintigraphy. We conclude that patients with thyroid incidentalomas can benefit from further diagnostic work-up including a thyroid scintigraphy.